Ovid Therapeutics (Ovid Therapeutics) Total Stockholders Equity : $78.28 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Total Stockholders Equity?

Ovid Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $78.28 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ovid Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $1.11. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ovid Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.20.

Ovid Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Ovid Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Total Stockholders Equity Chart

Ovid Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

70.02

43.63

179.75

132.27

87.80

Ovid Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															120.95	110.70	101.29	87.80	78.28

Ovid Therapeutics (NAS:OVID) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ovid Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(78.279	-	0)	/	70.784
	=	1.11

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ovid Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.268	+	14.43)	/	78.279
	=	0.20

Ovid Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovid Therapeutics (Ovid Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

1OT:Germany

Address

441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website

https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Executives

Jason Tardio	officer: Chief Commercial Officer	1460 BROADWAY, NEW YORK NY 10036
Takeda Pharmaceuticals U.s.a., Inc.	10 percent owner	ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Kevin Joseph Fitzgerald	director	C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Amit Rakhit	officer: CMO and PMO	C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Robert Michael Poole	director	200 W. HIGHLAND DR., #303, SEATTLE WA 98119
Jeffrey A Rona	officer: Chief Business Officer	500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeremy M Levin	director, 10 percent owner, officer: CEO
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Thomas Michael Perone	officer: SVP, General Counsel	1460 BROADWAY, NEW YORK NY 10036
Karen Bernstein	director	C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Millennium Pharmaceuticals Inc	10 percent owner	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Douglas E Williams	director	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Ana Ward	officer: SVP and General Counsel	C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Timothy Daly	officer: VP, Finance & Corp. Controller	20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854